OverviewSuggest Edit

    Octapharma is one of the largest human protein manufacturers, developing and producing human proteins from human plasma and human cell lines. Patients in many countries are treated with products in the following therapeutic areas: hematology (coagulation disorders), immunotherapy (immune disorders) and intensive care and emergency medicine.
    The Company develops and manufactures high-purity coagulation factor concentrates for patients with bleeding disorders; high-purity human immunoglobulin products for treating immune-mediated diseases and deficiencies and manufactures human plasma and protein products for treating critically ill or injured patients in intensive care and emergency settings.

    HQLachen, CH
    Employee Ratings3.1

    Latest Updates

    Employees (est.) (Dec 2018)8,314(+18%)
    Job Openings933
    Cybersecurity ratingBMore

    Key People/Management at Octapharma

    Flemming Nielsen

    Flemming Nielsen

    President, USA, Director
    Norbert Müller

    Norbert Müller

    Tobias Marguerre

    Tobias Marguerre

    Managing Director, Nordic AB, Director
    Frederic Marguerre

    Frederic Marguerre

    Shareholders' Representative President, Octapharma Plasma Inc. USA, Director
    Josef Weinberger

    Josef Weinberger

    Corporate Quality and Compliance Officer, Director
    Olaf Walter

    Olaf Walter

    Show more

    Octapharma Office Locations

    Octapharma has offices in Lachen, Charlotte, Hoboken, Miami and in 31 other locations
    Lachen, CH (HQ)
    Seidenstrasse 2
    Pyrmont, AU
    42/26-32 Pirrama Rd
    Wien, AT
    Oberlaaer Str. 235
    Baku, AZ
    96 Nizami St
    Minsk, BY
    503, Prospekt Dzerzhinskogo 8
    Anderlecht, BE
    Researchdreef 65
    Show all (39)

    Octapharma Financials and Metrics

    Summary Metrics

    Founding Date


    Octapharma Cybersecurity Score

    Cybersecurity ratingPremium dataset



    SecurityScorecard logo

    Octapharma Online and Social Media Presence

    Embed Graph

    Octapharma News and Updates

    Hemophilia Treatment Market Experts Ideas By Biotest AG, Kedrion, Octapharma AG, Baxter International

    The hemophilia treatment market was valued at US$ 14,454.81 million in 2019 and is expected to grow at a CAGR of 15.9% from 2020 to 2027 to reach US$ 44,089.71 million by 2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

    As Per New Research, Global Blood safety Market Growth – Report Studied Growing Factors Forecasts To 2024 along with key players such as ADMA Biologics Inc., Baxter International Inc., Creat Group, Octapharma AG, Shire Plc and TCS Biosciences Ltd.

    “Blood has been called the river of life, and for good reason. Blood transports life-sustaining oxygen and nutrients. Blood safety Vigilance is needed to help ensure proper balance between safety and the availability of blood.” Posted via Industry Today. Follow us on Twitter @IndustryToday

    Octapharma USA Sponsored Bombardier Blood Presented by Denver Mountain Climber During Special Hometown Screening

    DENVER, Dec. 4, 2018 /PRNewswire/ -- Colorado mountain climber Chris Bombardier, the first person with hemophilia to climb Mount Everest and the Seven Summits, was back in his hometown this past weekend to present Bombardier Blood, the documentary on his incredible journey sponsored by...

    Global Intravenous Immunoglobulin (IVIg) Market Top Key Players, Industry & Forecast By 2025 and Top Key Players like Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, Hualan Bio, CNBG

    Intravenous Immunoglobulin (IVIg) Market statistical examining report about the new Advances and Prospects in Intravenous Immunoglobulin (IVIg) Market, which serves current and Intravenous Immunoglobulin (IVIg) future specialized and financial points of interest of the Intravenous Immunoglobulin (IV…

    Octapharma USA Sponsors The Female Factor Women's Retreat in Monterey

    MONTEREY, Calif., Oct. 2, 2018 /PRNewswire/ -- Many women with bleeding disorders continue to be unaware of their undiagnosed disease, according to the Centers for Disease Control and Prevention (CDC), a fact that led to the formation of The Female Factor. Diagnosis and disease management ...

    Octapharma USA Partners with GutMonkey To Provide Hemophilia Patients Life-Changing Adventure Experience

    HOBOKEN, N.J., Sept. 12, 2018 /PRNewswire/ -- Continuing its commitment to help inspire people with bleeding disorders to challenge the limitations of chronic illness, Octapharma USA has become the exclusive sponsor of "Leading X San Juan Islands." Octapharma's grant to GutMonkey, an...

    Octapharma Blogs

    Update of Summary of Product Characteristics for Nuwiq® includes data on effective bleed protection with twice-weekly dosing with personalised prophylaxis

    Octapharma announced today that the European Medicines Agency has authorised an updated Summary of...

    Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress

    Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A...

    Octapharma communicates an update on the development of SubQ-8, a novel subcutaneous recombinant FVIII, at ISTH 2019

    Octapharma announced that an update on the clinical development plan and pre-clinical data with...

    Octapharma to Present New Data on Management of People with Haemophilia A or von Willebrand Disease at ISTH 2019

    New scientific data on Octapharma’s Haematology portfolio will be presented at the upcoming 27th...

    Octapharma Group reports strong results for 2018

    Reporting revenue of €1.8 billion and operating income of €346 millionGroup sales increased 4.5%...

    Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies

    Lachen, Switzerland – 26 November 2018 – Octapharma today announced that the Swiss Agency for...
    Show more

    Octapharma Frequently Asked Questions

    • When was Octapharma founded?

      Octapharma was founded in 1983.

    • Who are Octapharma key executives?

      Octapharma's key executives are Flemming Nielsen, Norbert Müller and Tobias Marguerre.

    • How many employees does Octapharma have?

      Octapharma has 8,314 employees.

    • Who are Octapharma competitors?

      Competitors of Octapharma include Grifols, CSL Behring and Insud Pharma.

    • Where is Octapharma headquarters?

      Octapharma headquarters is located at Seidenstrasse 2, Lachen.

    • Where are Octapharma offices?

      Octapharma has offices in Lachen, Charlotte, Hoboken, Miami and in 31 other locations.

    • How many offices does Octapharma have?

      Octapharma has 39 offices.